| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-05772SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP1-18644-0.02mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP1-18646-0.02mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB3572R-SP | |||
| Carrier Free | FAB3572RV-100UG | |||
| Carrier Free | FAB3572RU-100UG | |||
| Carrier Free | FAB3572RT-100UG | |||
| Carrier Free | FAB3572RS-100UG | |||
| Carrier Free | FAB3572RR-100UG | |||
| Carrier Free | FAB3572RN-100UG | |||
| Carrier Free | FAB3572RG-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-16893-20ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-89199-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-34658-0.1mg | |||
![Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody [NBP3-05772] - HepG2 cells were fixed for 10 minutes using 4% PFA and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-VEGFR2/KDR at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP3-05772-img0002.jpg "Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody [NBP3-05772] - HepG2 cells were fixed for 10 minutes using 4% PFA and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-VEGFR2/KDR at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.")
![Immunohistochemistry-Paraffin: VEGFR2/KDR/Flk-1 Antibody [NBP3-05772] - Analysis of a FFPE tissue section of mouse kidney using 1:200 dilution of VEGFR2 antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-Immunohistochemistry-Paraffin-NBP3-05772-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody (4H3) - Azide and BSA Free [NBP1-18644] - VEGFR2/KDR/Flk-1 Antibody (4H3) [NBP1-18644] - IF double staining of human KDR in a co-culture of PAE-Flt-1, PAE-KDR and PAE-FLT-4 with (A) mouse anti-human KDR, (B) rabbit antihuman KDR (C) DAPI and (D) merged. Conjugated secondary antibody: goat anti-rabbit ALEXA Flour (1:600) and goat anti-mouse PE.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-4H3-Immunocytochemistry-Immunofluorescence-NBP1-18644-img0017.jpg "Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody (4H3) - Azide and BSA Free [NBP1-18644] - VEGFR2/KDR/Flk-1 Antibody (4H3) [NBP1-18644] - IF double staining of human KDR in a co-culture of PAE-Flt-1, PAE-KDR and PAE-FLT-4 with (A) mouse anti-human KDR, (B) rabbit antihuman KDR (C) DAPI and (D) merged. Conjugated secondary antibody: goat anti-rabbit ALEXA Flour (1:600) and goat anti-mouse PE.")
![Flow Cytometry: VEGFR2/KDR/Flk-1 Antibody (4H3) [NBP1-18644] - Analysis using the Biotin conjugate of NBP1-18644. Staining of VEGFR-2/KDR expression in HUVE cells.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-4H3-Flow-Cytometry-NBP1-18644-img0011.jpg)
![Flow Cytometry: VEGFR2/KDR/Flk-1 Antibody (4H3) [NBP1-18644] - Fig. 1: Flow analysis of VEGF R2/KDR/Flk-1 expression in primary human dermal mivrovascular endothelial cells (HDMVEC) and human umbilical vein endothelial cells (HUVEC).](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-4H3-Flow-Cytometry-NBP1-18644-img0008.jpg)
![ELISA: VEGFR2/KDR/Flk-1 Antibody (4H3) [NBP1-18644] - 1 Sandwich-ELISA using soluble KDR (D7) as standard. Mouse anti-human VEGFR-2 was used as capture antibody, Biotinylated rabbit anti-human VEGFR-2 was used for detection.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-4H3-ELISA-NBP1-18644-img0006.jpg)
![ELISA: VEGFR2/KDR/Flk-1 Antibody (4H3) [NBP1-18644] - Total lysate from PAE/KDR cells was measured for expression of VEGFR- 1/KDR by a standard Sandwich ELISA using a mouse monoclonal anti-human VEGFR-1 antibody for capturing and a Biotin conjugated rabbit polyclonal anti-human VEGFR-1 antibody for detection. Total lysate from PAE/Flt-1 and PAE/FLT-4 was used as negative control. As positive control, total lysate from PAE/Flt-1 was spiked with recombinant human sKDR.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-4H3-ELISA-NBP1-18644-img0018.jpg)
![Western Blot: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - VEGFR2/KDR/Flk-1 Antibody (20I6) [NBP1-18646] - Recombinant human endogenous soluble VEGFR-2/KDR (esKDR) was produced in insect cells. Western blot was performed using our monoclonal anti-VEGFR-2 recognizing the soluble as well as the transmembrane form of KDR (left panal) and our new poyclonal antibody directed against the unique C-terminal end of the endogenous sKDR (CGRETILDHSAEAVGMP) recognizing solely the endogenous form but not sKDR (D7) and sKDR (D7)-Fc consisting of the full extraplasmatic domain. The endogenous sKDR generated by alternative splicing consists of the first 6 Ig-like loops with a unique c-terminal end.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-20I6-Western-Blot-NBP1-18646-img0006.jpg "Western Blot: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - VEGFR2/KDR/Flk-1 Antibody (20I6) [NBP1-18646] - Recombinant human endogenous soluble VEGFR-2/KDR (esKDR) was produced in insect cells. Western blot was performed using our monoclonal anti-VEGFR-2 recognizing the soluble as well as the transmembrane form of KDR (left panal) and our new poyclonal antibody directed against the unique C-terminal end of the endogenous sKDR (CGRETILDHSAEAVGMP) recognizing solely the endogenous form but not sKDR (D7) and sKDR (D7)-Fc consisting of the full extraplasmatic domain. The endogenous sKDR generated by alternative splicing consists of the first 6 Ig-like loops with a unique c-terminal end.")
![Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - HMEC-1 CRL-3243 cells, stained with 1:50 VEGFR2/KDR/Flk-1 antibody (NBP1-18645AF488) (green) and DAPI (blue). Image from verified customer review.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-20I6-Azide-and-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-18646-img0016.jpg)
![Flow Cytometry: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - VEGFR2/KDR/Flk-1 Antibody (20I6) [NBP1-18646] - Analysis with primary human dermal lymphatic endothelial cells(HDLEC).](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-20I6-Flow-Cytometry-NBP1-18646-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - VEGFR2/KDR/Flk-1 Antibody (20I6) [NBP1-18646] - Staining (green) of VEGFR-2 (KDR) in primary human umbilical vein endothelial cells (HUVEC) with anti-human VEGFR-2 (Cl.4) (7,5ug/ml) and counter staining of nuclei with Dapi. As secondary antibody goat anti-mouse ALEXA Flour 488 (Dianova) was used 1:600.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-20I6-Immunocytochemistry-Immunofluorescence-NBP1-18646-img0015.jpg)
![Western Blot: VEGFR2/KDR/Flk-1 [p Tyr1175] Antibody [NBP3-16893] - Western blot analysis of extracts of NIH/3T3 cells, using VEGFR2/KDR/Flk-1 antibody (NBP3-16893) at 1:1000 dilution.NIH/3T3 cells were treated by EGF (100 ng/ml) at 37C for 30 minutes after serum-starvation overnight. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 180s.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-[p-Tyr1175]-Antibody-Western-Blot-NBP3-16893-img0001.jpg "Western Blot: VEGFR2/KDR/Flk-1 [p Tyr1175] Antibody [NBP3-16893] - Western blot analysis of extracts of NIH/3T3 cells, using VEGFR2/KDR/Flk-1 antibody (NBP3-16893) at 1:1000 dilution.NIH/3T3 cells were treated by EGF (100 ng/ml) at 37C for 30 minutes after serum-starvation overnight. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 180s.")
![Western Blot: VEGFR2/KDR/Flk-1 [p Tyr1175] Antibody - Azide and BSA Free [NBP3-16893] - Western blot analysis of lysates from A-431 cells, using VEGFR2/KDR/Flk-1 Rabbit pAb at 1:500 dilution. A-431 cells were treated by EGF (100 ng/ml) at 37C for 30 minutes after serum-starvation overnight.Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit.Exposure time: 1s.](http://images.novusbio.com/fullsize/nbp3-16893_rabbit-vegfr2-kdr-flk-1-p-tyr-1175-pab-52202511374126.jpg)
![Western Blot: VEGFR2/KDR/Flk-1 [p Tyr1175] Antibody - Azide and BSA Free [VEGFR2/KDR/Flk-1] - Western blot analysis of lysates from A-431 cells, using VEGFR2/KDR/Flk-1 Rabbit pAb at 1:500 dilution. A-431 cells were treated by EGF (100 ng/ml) at 37C for 30 minutes after serum-starvation overnight.Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit .Exposure time: 1s.](http://images.novusbio.com/fullsize/nbp3-16893_rabbit-vegfr2-kdr-flk-1-p-tyr-1175-pab-52202517333836.jpg)
![Immunohistochemistry-Paraffin: VEGFR2/KDR/Flk-1 Antibody [NB100-686] - Formalin fixed paraffin embedded human angiosarcoma stained with Flk-1 antibody (NB100-686).](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-Immunohistochemistry-Paraffin-NB100-686-img0004.jpg "Immunohistochemistry-Paraffin: VEGFR2/KDR/Flk-1 Antibody [NB100-686] - Formalin fixed paraffin embedded human angiosarcoma stained with Flk-1 antibody (NB100-686).")
![Flow Cytometry: VEGFR2/KDR/Flk-1 Antibody (001) [NBP2-89199] - Analysis of Human VEGFR2(CD309) expression on HUVEC cells. Cells were stained with purified anti-Human VEGFR2(CD309), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.](http://images.novusbio.com/fullsize/VEGFR2-KDR-Flk-1-Antibody-001-Flow-Cytometry-NBP2-89199-img0001.jpg "Flow Cytometry: VEGFR2/KDR/Flk-1 Antibody (001) [NBP2-89199] - Analysis of Human VEGFR2(CD309) expression on HUVEC cells. Cells were stained with purified anti-Human VEGFR2(CD309), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.")